EU number	Invented nam	Strength	Pharmaceutical Form	Route of administration	Packaging	Content	Package size
EU/1/4/301/001	Quintanrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass); suspension:vial (glass)	0.5 ml	1 vial + 1 vial
EU/1/4/301/002	Quintanrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass); suspension:vial (glass)	0.5 ml	100 vials + 100 vials
EU/1/4/301/003	Quintanrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass); suspension:vial (glass)	1 ml	1 vial + 1 vial
EU/1/4/301/004	Quintanrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass); suspension:vial (glass)	1 ml	100 vials + 100 vials
EU/1/4/301/005	Quintanrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass); suspension:vial (glass)	5 ml	50 vials + 50 vials

--[1] 1 dose (0.5 ml) contains:

Diphtheria toxoid*	≥ 30 IU
Tetanus toxoid*	≥ 60 IU
Inactivated Bordetella pertussis strain**	≥ 4 IU
Hepatitis B virus surface antigen recombinant** (S protein)***	10 micrograms

Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) [2]	2.5 micrograms
conjugated to tetanus toxoid as a carrier	5-10 micrograms

* adsorbed on aluminium hydroxide hydrated Total: 0.26 milligrams $Al^{3}+$
** adsorbed on aluminium phosphate Total: 0.40 milligrams $Al^{3}+$
*** produced in Saccharomyces cerevisiae cells by recombinant DNA technology